

Treatment of rewarming shock with PDE-inhibitors - Temperature dependent effects on transport and metabolism of cAMP and cGMP

Selli AL, Kalasho A, Smaglyukova N, Kondratiev T, Lyså R, Sager G, Tveita T, Ravna AW, Dietrichs ES

Experimental and Clinical Pharmacology Research Group, Department of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway

Introduction

- Hypothermia below 35°C
- Rewarming shock contributing to 25-40% mortality
- Accidental and therapeutic hypothermia
- cAMP and cGMP modulates cardiovascular function

	cAMP	cGMP
Metabolizing enzyme	PDE3	PDE5
Extrusion pump	ABCC4	ABCC5



Ullstinden December 8th 2018, -13°C


Objectives

- Pharmacokinetic properties of 6 PDE-inhibitors during hypothermia
- Cellular extrusion, PDE-inhibition and intracellular access
- Sildenafil (Viagra), Milrinone, Levosimendan, Amrinone, Pentoxifylline, Vardenafil
- Clinical relevance



cGMP increase

- Vasodilation, reducing afterload
- Shown beneficial effects on cardiac output




Håheim B, Kondratiev T, Dietrichs ES, Tveita T: The beneficial hemodynamic effects of afterload reduction by sodium nitroprusside during rewarming from experimental hypothermia. *Cryobiology* 2017, 77:75.

The role of cGMP

SNP

Vascular smooth muscle

synthase; GC, guanylyl cyclase; PDE5, cGMP-dependent



Sildenafil

Illustration by Erik Sveberg Dietrichs

phosphodiesterase (type 5)

Methods





Illustration of inside-out-vesicles by Roy Lysaa


Cellular extrusion







IC-50 values



IC-50: concentration at which the drug has reduced cGMP transport through the efflux pumps by 50%.

Mean IC-50 values for Sildenafil

Conclusion

- Preliminary results
- Lower IC-50 values at lower temperatures?
- Further investigation
- PDE-inhibition and intracellular access


Acknowledgements


- Experimental and Clinical Pharmacology Research Group, Department of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway
- Adrina Kalasho
- Natalia Smaglyokova
- Timofey Kondratyev
- Roy Lysaa
- Georg Sager
- Torkjel Tveita
- Aina Westerheim Ravna
- Erik Sveberg Dietrichs





- Har studiedesignet noen begrensninger?
- Er det noen svakheter?
- Er det noe vi ikke har gjort eller inkludert i studien som kunne vært relevant?
- Hva slags konsekvenser vil mine forskningsresultater kunne ha?





- PDE5-inhibitors: Sildenafil and Vardenafil
- PDE3-inhibitors: Milrinone, Amrinone and Levosimendan (calsium sensitizer)
- Unselective PDE-inhibitor: Pentoxifylline